TRPV1 recombinant proteins and antibodies

TRPV1 is also known as capsaicin receptor, transient receptor potential cation channel subfamily V member 1, vanilloid receptor 1 (VR1), and Osm-9-like TRP channel 1 (OTRPC1). American scientists David Julius and Ardem Patapoutian won the 2021 Nobel Prize in Physiology or Medicine for discovering that it is a temperature and touch receptor, and TRPV1 is also sought after by industry insiders as a target for pain treatment.

TRPV1 is mainly highly expressed in DRG, trigeminal ganglion (TG) and spinal cord. Under normal physiological conditions, TRPV1 plays a key role in thermal sensation, oral sensation, proteasome activity, autophagy regulation, energy homeostasis, muscle physiology, gastrointestinal motility, inflammatory mediator release, and crosstalk between the immune system and the sensory nervous system. More TRPV1 mechanism of action >>

TRPV1 has become popular as a target for pain treatment. Currently, there are 106 TRPV1-targeting drugs in the world, including small molecule drugs, synthetic peptides, siRNA, etc., among which small molecule drugs dominate. To assist in the development of TRPV1 drugs, DIMA BIOTECH has developed a series of spot products targeting TRPV1, including recombinant proteins, Synthetic Nnanodisc full-length multi-span membrane proteins and biotin-labeled antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank for TRPV1 targets, which can screen out the lead antibody molecules required by customers in just 28 days. For more details, please contact us.